JP2023527054A5 - - Google Patents
Info
- Publication number
- JP2023527054A5 JP2023527054A5 JP2022572765A JP2022572765A JP2023527054A5 JP 2023527054 A5 JP2023527054 A5 JP 2023527054A5 JP 2022572765 A JP2022572765 A JP 2022572765A JP 2022572765 A JP2022572765 A JP 2022572765A JP 2023527054 A5 JP2023527054 A5 JP 2023527054A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- seq
- composition according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063031854P | 2020-05-29 | 2020-05-29 | |
| US63/031,854 | 2020-05-29 | ||
| PCT/EP2021/064312 WO2021239928A2 (en) | 2020-05-29 | 2021-05-28 | Treatment of cardiometabolic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527054A JP2023527054A (ja) | 2023-06-26 |
| JP2023527054A5 true JP2023527054A5 (https=) | 2024-05-30 |
Family
ID=76269736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572765A Pending JP2023527054A (ja) | 2020-05-29 | 2021-05-28 | Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12410254B2 (https=) |
| EP (2) | EP4157873A2 (https=) |
| JP (1) | JP2023527054A (https=) |
| KR (1) | KR20230018446A (https=) |
| CN (1) | CN115667309A (https=) |
| AU (1) | AU2021279277A1 (https=) |
| BR (1) | BR112022023438A2 (https=) |
| CA (1) | CA3183611A1 (https=) |
| IL (1) | IL298299A (https=) |
| WO (1) | WO2021239928A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237647A (zh) * | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| WO2022106460A2 (en) * | 2020-11-18 | 2022-05-27 | Astrazeneca Ab | Steroid sparing |
| CN120392997A (zh) | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087335A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
| WO2003087327A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| CN1745170A (zh) | 2002-12-17 | 2006-03-08 | 米迪缪尼疫苗股份有限公司 | 生物活性材料的高压喷雾干燥 |
| SG144925A1 (en) * | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR20160070165A (ko) * | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| CN107110939B (zh) * | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| FI20177098A1 (fi) * | 2017-08-29 | 2019-03-01 | Leppaeluoto Juhani | Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen |
| JP7013632B2 (ja) * | 2018-09-18 | 2022-02-01 | アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド | 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体 |
| CA3119749A1 (en) * | 2018-11-15 | 2020-05-22 | Ampel Biosolutions, Llc | Machine learning disease prediction and treatment prioritization |
-
2021
- 2021-05-28 EP EP21729861.1A patent/EP4157873A2/en not_active Withdrawn
- 2021-05-28 IL IL298299A patent/IL298299A/en unknown
- 2021-05-28 BR BR112022023438A patent/BR112022023438A2/pt unknown
- 2021-05-28 CA CA3183611A patent/CA3183611A1/en active Pending
- 2021-05-28 AU AU2021279277A patent/AU2021279277A1/en not_active Abandoned
- 2021-05-28 WO PCT/EP2021/064312 patent/WO2021239928A2/en not_active Ceased
- 2021-05-28 EP EP24220273.7A patent/EP4566667A3/en active Pending
- 2021-05-28 CN CN202180037656.9A patent/CN115667309A/zh active Pending
- 2021-05-28 JP JP2022572765A patent/JP2023527054A/ja active Pending
- 2021-05-28 KR KR1020227045818A patent/KR20230018446A/ko active Pending
-
2023
- 2023-12-22 US US18/394,365 patent/US12410254B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9783589B2 (en) | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases | |
| JP2023527054A5 (https=) | ||
| Billiau et al. | Anti‐interferon‐γ antibody protects mice against the generalized Shwartzman reaction | |
| AU2019279946A1 (en) | Methods for treating atopic dermatitis by administering an IL-4R antagonist | |
| RU2587620C2 (ru) | Способы лечения аутоиммунных заболеваний антагонистами dll4 | |
| JP2022169504A5 (https=) | ||
| CN103458926A (zh) | 改进的高浓度抗TNF α 抗体液体制剂 | |
| JP7045327B2 (ja) | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン | |
| EP2609118A2 (en) | Anti-ox40 antibodies and methods of using the same | |
| KR20170135967A (ko) | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 | |
| HUE030701T2 (hu) | Tweak-kötõ antitestek | |
| JP2024524159A5 (https=) | ||
| KR20230044312A (ko) | 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로 | |
| MX2013003920A (es) | Metodos para el tratamiento de la psoriasis. | |
| CA2676185A1 (en) | Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis | |
| JP2022542035A (ja) | 抗ｐｒｅ－ｓ１ ｈｂｖ抗体を用いるｈｂｖ感染症の治療方法 | |
| JP7645555B2 (ja) | Ｐｄ－ｌ１タンパク質が含まれた融合タンパク質およびその用途 | |
| JP2024116343A (ja) | ヘパピティスｂウイルス複製およびヘパピティスｂウイルス表面抗原分泌の抑制方法 | |
| AU2005232653B2 (en) | Methods of treating autoimmune and inflammatory diseases | |
| CN116507365A (zh) | 抗ox40抗体在治疗肿瘤或癌症中的应用 | |
| JP2022527542A5 (https=) | ||
| CN108992671B (zh) | 一种药物组合物及其制备治疗肝损伤的药物中的用途 | |
| BR112020025504A2 (pt) | Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido | |
| WO2012097288A1 (en) | Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor | |
| CN115734971A (zh) | 抗ang-2抗体及其用途 |